Lack of clinical AIDS in SIV-infected sooty mangabeys with significant CD4+ T cell loss is associated with double-negative T cells

Jeffrey M. Milush,1,2 Kiran D. Mir,1,3 Vasudha Sundaravaradan,3 Shari N. Gordon,4 Jessica Engram,4,5 Christopher A. Cano,1 Jacqueline D. Reeves,5 Elizabeth Anton,5 Eduardo O’Neill,6 Eboneé Butler,5 Kathy Hancock,6 Kelly S. Cole,7 Jason M. Brenchley,8 James G. Else,9 Guido Silvestri,9 and Donald L. Sodora1,3

1Division of Infectious Disease, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 2Division of Experimental Medicine, Department of Medicine, UCSF, San Francisco, California, USA. 3Seattle Biomedical Research Institute, Seattle, Washington, USA. 4University of Pennsylvania, Philadelphia, Pennsylvania, USA. 5Monogram Biosciences, South San Francisco, California, USA. 6Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 7University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 8Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA. 9Yerkes National Primate Research Center, Emory University, Emory Vaccine Center, Atlanta, Georgia, USA.

SIV infection of natural host species such as sooty mangabeys results in high viral replication without clinical signs of simian AIDS. Studying such infections is useful for identifying immunologic parameters that lead to AIDS in HIV-infected patients. Here we have demonstrated that acute, SIV-induced CD4+ T cell depletion in sooty mangabeys does not result in immune dysfunction and progression to simian AIDS and that a population of CD3+CD4+CD8- T cells (double-negative T cells) partially compensates for CD4+ T cell function in these animals. Passaging plasma from an SIV-infected sooty mangabey with very few CD4+ T cells to SIV-negative animals resulted in rapid loss of CD4+ T cells. Nonetheless, all sooty mangabeys generated SIV-specific antibody and T cell responses and maintained normal levels of plasma lipopolysaccharide. Moreover, all CD4-low sooty mangabeys elicited a de novo immune response following influenza vaccination. Such preserved immune responses as well as the low levels of immune activation observed in these animals were associated with the presence of double-negative T cells capable of producing Th1, Th2, and Th17 cytokines. These studies indicate that SIV-infected sooty mangabeys do not appear to rely entirely on CD4+ T cells to maintain immunity and identify double-negative T cells as a potential subset of cells capable of performing CD4+ T cell–like helper functions upon SIV-induced CD4+ T cell depletion in this species.

Introduction

Disease progression during pathogenic HIV/SIV infection has been defined historically by 2 strongly predictive parameters: plasma viral load and peripheral CD4+ T cell levels. However, it is becoming increasingly clear that HIV/SIV pathogenesis results from more than continuous virus replication and a coincident decline of target cells. For example, CD4+ T cells in mucosal compartments are severely depleted very early after infection, and yet progression to AIDS is significantly delayed (1–5). Furthermore, the elevated levels of generalized immune activation observed during pathogenic infections are more predictive of disease progression than viral load (6–8). The identification of natural host species such as sooty mangabeys and African green monkeys (AGMs) that replicate SIV to high levels but generally do not exhibit clinical signs of AIDS has been invaluable. Through comparison of pathogenic and nonpathogenic infections, we can infer the important pathogenic factors. For example, SIV-infected natural hosts experience an early and rapid depletion of mucosal CD4+ T cells to an extent similar to that seen in HIV patients (9–12) as well as adaptive immune responses that are comparable to those in pathogenic HIV/SIV infections (13, 14). One striking distinction of the natural SIV infections is the maintenance of low levels of generalized immune activation during the chronic phase of the infection (at times after 28 dpi) (7, 8, 15–19).

We previously observed that 2 SIV-infected sooty mangabeys infected by SIVsmm via plasma transfer in October 2000 exhibited a dramatic CD4+ T cell decline (< 100 cells/µl blood) yet maintained low levels of immune activation during chronic infection (19). The CD4+ T cell depletion occurred within all tissue samples examined, and the CD4-low phenotype in these mangabeys was associated with the presence of a multitropic (R5/X4/R8-using) SIVsmm (19). Unlike the inoculum, this multitropic SIVsmm was able to infect CD4+ T cells expressing CXCR4, which includes more than 90% of CD4+ T cells in sooty mangabeys (19). Importantly, these mangabeys have remained free of clinical signs of simian AIDS for the past 10 years. Here, we undertake a passage of the multitropic SIVmm from a CD4-low mangabey to 3 additional mangabeys and investigate the immunologic mechanisms by which these SIV-infected mangabeys can remain free of disease despite AIDS-defining CD4+ T cell levels.

Results

Passage of multitropic SIVmm results in rapid depletion of CD4+ T cells.

To further investigate the CD4-low phenotype observed in 2 SIV-infected sooty mangabeys (19), we passaged SIVmm from the previously identified CD4-low mangabey SM2 through intravenous
transfer of plasma to 3 additional mangabeys, SM7, SM8, and SM9 (preinfection CD4+ T cell levels ranged 600–1200 CD4+ T cells/μl blood) and continued monitoring these animals longitudinally (Figure 1A). Inoculation of the multitropic SIV/smmb resulted in a peak plasma viral load between 10^6 and 10^8 copies of viral RNA/ml of plasma (Figure 1B) and coincided with a dramatic decline in peripheral blood CD4+ T cells (Figure 1A). Within 14–21 days post infection (dpi), CD4+ T cells had declined to less than 200/μl of blood and established a CD4 set point below 50 CD4+ T cells/μl blood by 1 month after infection (Figure 1A). A viral set point ranging from 10^3 to 10^4 copies of viral RNA/ml of plasma was established around 3 months after infection and was maintained throughout the study period (Figure 1B). CD8+ T cells ranged from 1000 to 2000 CD8+ T cells/μl blood prior to infection and exhibited a transient decline after SIV infection, then subsequently returned to near baseline levels (Figure 1C). The rapid depletion of CD4+ T cells in SM7, SM8, and SM9 suggested that the depletion was virally mediated, and indeed following plasma transfer, the SIV replicating in these mangabeys retained the ability to utilize both CCR5 and CXCR4 (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI44876DS1).

Generalized depletion of CD4+ T cells from multiple sites in CD4-low mangabeys. Infection of rhesus macaques with an X4-tropic SIV or SHIV results in a rapid depletion of naive CD4+ T cells from blood and peripheral lymphoid tissue and a gradual loss of mucosal CD4+ T cells (18). Assessing the kinetics of CD4+ T cell depletion in the 3 CD4-low mangabeys derived from viral passage identified a rapid depletion of both peripheral blood (Figure 1A) and mucosal CD4+ T cells (Figure 1D). The depletion of CD4+ T cells was observed in the rectal mucosa, bronchoalveolar lavage (BAL), and LNs as early as 14 dpi. By 180 dpi, the CD4+ T cells made up less than 1% of T cells in the rectal mucosa and LNs and 1%–2% in the BAL (Figure 1D). A summary of the frequency of CD4+ T cells before and after SIV infection, presented as the percentage within the CD3+ T cells, is provided for each compartment (Supplemental Table 1). Each mangabey began with a comparable percentage of naive (CD95–) and memory (CD95+) CD4+ T cells in peripheral blood (Figure 1C). The rapid depletion of CD4+ T cells in SM7, SM8, and SM9 suggested that the depletion was virally mediated, and indeed following plasma transfer, the SIV replicating in these mangabeys retained the ability to utilize both CCR5 and CXCR4 (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI44876DS1).
A cross-sectional assessment of plasma LPS found that all 5 CD4-low mangabeys, including SM1 and SM2 that had each been infected by 50 dpi, where they have remained (Supplemental Figure 2). However, this effector memory skewing was not observed in mangabey SM9, which maintained predominately central memory CD4+ T cells in the peripheral blood after the SIV infection (Figure 2, B and C). Within the CD8+ T cells, SM7, SM8, and SM9 each exhibited a lower level of naive cells compared with preinfection (Figure 2D), although the proportion of central and effector memory CD8+ T cells was similar to that observed prior to infection (Figure 2, E and F).

**CD4 depletion in SIV-infected mangabeys is not associated with increased immune activation.** Both HIV and pathogenic SIV infections result in severe and persistent mucosal CD4+ T cell depletion as well as elevated immune activation, a finding that led to the bacterial translocation hypothesis and suggested a role for bacterial products in perpetuating HIV-associated immune activation (17, 20). In contrast, SIVsmm infection of sooty mangabeys results in only transient increases in immune activation as measured by T cell proliferation (Ki-67 expression) (9, 19, 21), despite a coincident depletion of gut CD4+ T cells (9). In the CD4-low mangabeys studied here, Ki-67 staining also identified a transient increase in the proliferation of CD8+ T cells and to some extent the CD4+ T cells that was limited to the first 4 weeks post infection (wpi) (Figure 3, A and B). Furthermore, an assessment of the markers of T cell activation, CD38, and HLA-DR coexpression, identified a transient increase in coexpression on CD8+ T cells in the SIV-infected mangabeys; however, these levels returned to near preinfection levels by 50 dpi, where they have remained (Supplemental Figure 2). A cross-sectional assessment of plasma LPS found that all 5 CD4-low mangabeys, including SM1 and SM2 that had each been CD4-low for 9 years, maintained low plasma LPS concentrations (3–20 pg/ml), similar to uninfected and SIV-infected CD4-healthy mangabeys (Figure 3C). Furthermore, a longitudinal assessment of plasma LPS concentrations indicated a low transient increase during acute infection that returned to normal and was otherwise maintained throughout infection (Figure 3D). Only SM9 exhibited an increase in plasma LPS above the normal range of SIV-negative mangabeys (0–40 pg/ml) (9); however, this increase was quickly resolved (Figure 3D). These findings differed from previous reports assessing pathogenic SIV infection in rhesus macaques that have elevated plasma LPS levels (20). To further investigate mucosal integrity, the expression of occludin, a key molecule in tight junction formation, was assessed in rectal biopsies of SM7, SM8, and SM9. We observed that all 3 mangabeys maintained normal or slightly elevated expression of occludin in both acute and chronic infection (Figure 3E). In contrast, occludin expression in a group of SIV-infected rhesus macaques was decreased between 10- and 84-fold compared with uninfected macaques at both acute and chronic time points (Figure 3F). Taken together, these data suggest that CD4-low mangabeys may maintain mucosal integrity in part through preserved occludin expression, thereby preventing increases in plasma LPS and generalized immune activation despite the depletion of CD4+ T cells at the intestinal mucosa.

**Preserved adaptive immune function in CD4-low SIV+ mangabeys.** We assessed the ability of the immune systems in the CD4-low mangabeys to mount an adaptive immune response to both SIV and a neoantigenic challenge, influenza vaccine. Despite the rapid and severe CD4 depletion in SM7, SM8, and SM9, SIV Env-specific antibodies were detectable by 28 dpi (Figure 4A). Furthermore, following SIV-specific peptide pulsing and intracellular cytokine staining, CD8+ T cells from all 5 CD4-low mangabeys were capable of producing TNF-α or IFN-γ (Figure 4, B and C) at levels similar to those previously reported for CD4-healthy SIV-infected mangabeys (22). In addition, all 5 CD4-low mangabeys received a multivalent vaccine containing both an A/Solomon Islands/3/2006–like (H1N1-like) virus and an A/Wisconsin/67/2005-like (H3N2-like) virus. Upon
intramuscular injection of the first influenza vaccine, all 5 CD4-low mangabeys exhibited increased CD8+ T cell proliferation and 4 of 5 exhibited increased CD4+ T cell proliferation (Supplemental Figure 3, A and B). This proliferative response was transient, as proliferation levels returned to baseline by 21 days after vaccination. Following a second influenza vaccination (10 months after the first), an influenza-specific antibody response was detected in all 5 CD4-low mangabeys as measured by microneutralization for H1N1 and 4 of 5 for H3N2 (Table 1). The less sensitive hemagglutination inhibition (HI) assay was also performed, and 3 of 5 CD4-low mangabeys seroconverted with HI titers between 40 and 453 (data not shown). The less sensitive hemagglutination inhibition (HI) assay was also performed, and 3 of 5 CD4-low mangabeys seroconverted with HI titers between 40 and 453 (data not shown). (D) Concentration of plasma LPS during SIV infection of SM7, SM8, and SM9. (E and F) Fold change of occludin mRNA expression in SM7, SM8, and SM9 or RMs 1–6 during acute (2–15 dpi) and chronic (184 dpi) infection or at time of necropsy. Fold change was determined relative to uninfected control animals of the same species; the fold change is considered increased or decreased when it is greater than 2 SD from the mean expression in uninfected animals (represented by the area between the dotted lines).

**Potential helper functions of CD3+CD4-CD8+ T cells.** We hypothesized that in the absence of CD4+ T cells, another immune cell subset is likely performing CD4-like helper functions in the SIV-infected CD4-low mangabeys. One immune cell subset of interest was the CD3+CD4-CD8+ double-negative (DN) T cells due to the finding that both SIV-infected and uninfected sooty mangabeys exhibit relatively high levels of DN T cells primarily expressing the α/β T cell receptor in peripheral blood (Figure 5A). Prior to SIV infection, SM7, SM8, and SM9 had similar frequencies of DN T cells in each respective tissue compartment examined with a larger percentage of the CD4-low T cells being observed in LNs, BAL, and rectal biopsies and the lowest percentage in the blood (Supplemental Table 1). Following infection, the DN T cell levels increased slightly (between 200 and 500 cells/mm3 blood) in the peripheral blood of SM7, SM8, and SM9 as the CD4+ T cells were depleted (Figure 5 and Supplemental Table 1). Interestingly, the largest percentage increase in the DN T cell population was within the LNs (percentage increased by 2-fold) and rectal mucosa (percentage increased 3-fold), while the BAL exhibited a more modest DN T cell increase (Supplemental Table 1). DN T cells maintained a primarily central memory phenotype throughout infection (Figure 5C), suggesting they may be antigen-experienced T cells that have downregulated the expression of CD4 and/or CD8, similarly to what has been observed in AGMs (24). In SM7, SM8, and SM9, SIV infection resulted in a transient increase in proliferation of the DN T cells, with peak proliferation at 20 dpi, similar to CD8+ and CD4+ T cells (Figure 3, A and B, compared with Supplemental Figure 4A). Similarly, CD38 and HLA-DR coexpression on DN T cells was acutely elevated; however, by 28 dpi, it had returned to baseline levels (Supplemental Figure 4B). Furthermore, an early, transient increase in DN T cell proliferation following influenza vaccination indicated that these cells have the potential to respond during a vaccination (Supplemental Figure 4C). To assess the functionality of isolated DN T cells, we stimulated them with anti-CD3 and anti-CD28 antibodies to mimic T cell receptor stimulation and evaluated their cytokine mRNA levels with real-time PCR. DN T cells from CD4-low mangabeys increased the expression of IFN-γ (Th1), IL-4 (Th2), and IL-17 (Th17) cytokines between 300- and 8000-fold in response
The identification of CD4-low mangabeys provides additional evidence for the importance of the low levels of immune activation in preventing the onset of simian AIDS in the natural host species (12, 16, 25). These studies provide keys to unraveling the complexities of HIV-induced disease progression and for understanding a subset of HIV-infected long-term nonprogressors, termed viremic nonprogressors, which display an immunologic profile similar to the natural hosts of SIV (low immune activation despite persistently high viral replication) (26). Immune activation is the strongest correlate of disease progression in pathogenic HIV/SIV infection (6, 27, 28) and several models have been suggested to identify the key elements driving the elevated immune activation (29, 31). One model associates rapid disease progression in the SIV-infected macaques with the translocation of commensal organisms resulting from the inability to replenish CD4+ memory T cells in the intestinal mucosa (32, 33). It is difficult to reconcile how our cohort of CD4-low mangabeys, or any SIV-infected mangabey, could sustain extensive depletion of mucosal CD4+ T cells (for up to 9 years in 2 mangabeys) without concomitant increases in plasma LPS or immune activation, arguing that the bacterial translocation hypothesis is more complex than just memory CD4+ T cell depletion. Based on our data, we envision 2 possible scenarios: first, that the ability of CD4-low SIV-infected mangabeys to maintain low levels of chronic immune activation prevents alterations in intestinal tight junctions, including maintained expression of occludin, which can be reduced in the presence of proinflammatory cytokines such as IL-1β and TNF-α (33, 34). Moreover, low levels of immune activation may allow for the preserved function of numerous immune cell subsets, including DN T cells and the remaining few CD4+ T cells, which would in turn contribute to maintaining normal immune responses to SIV and other foreign antigens. Alternatively, a second hypothesis is that DN T cells may play a direct role in preventing bacterial translocation and the onset of immune activation. Indeed, we observed that DN T cells are present at elevated frequencies in mucosal compartments compared with the blood (Supplemental Table 1). Moreover, DN T cells from CD4-low sooty mangabeys can produce IL-17 (Figure 5D), a cytokine important in maintaining mucosal integrity. Together, these data suggest that in sooty mangabeys, DN T cells may play a role in actively maintaining mucosal integrity and low levels of immune activation that in turn provide an environment in which other immune cells can also remain functional.

Data from HIV-infected elite controller individuals indicate that delayed HIV disease progression is associated with superior control of viral replication by the host’s adaptive immune responses. The SIV-infected natural hosts do not fit within this paradigm, as disease progression is averted in the presence of relatively high levels of viral replication and detectable, but not superior, adaptive immune responses (35). As CD4+ T cell help is required for the optimal activation and early clonal expansion of cell-mediated and humoral immune responses (36, 37), it was initially perplexing that the
CD4-low mangabeys were able to develop both SIV-specific antibody and T cell responses as well as influenza-specific antibodies. Indeed, HIV-infected patients with CD4 counts below 100 cells/μl have difficulties developing influenza-specific antibodies following an influenza vaccination (38). Moreover, the CD4-low SIV+ mangabeys have maintained immune health and immune function, as no evidence of opportunistic infections or cancers have been observed. One explanation for this outcome is that sooty mangabeys have evolved the potential to rely on a very small number of CD4+ T cells. Alternatively, our results suggest that a non-CD4+ immune cell subset may be compensating for the loss of CD4+ T cells, and we propose that DN T cells are fulfilling this role. Recently, Beaumier et al. described a CD3+CD4− T cell subset in SIV-infected AGMs that is resistant to SIV infection, functional, MHC class II restricted, and maintains effector functions normally attributed to CD4+ T cells (24). The DN T cells in our CD4-low SIV-infected mangabeys are primarily central memory ββ-TCR+ cells, which do not express the γδ TCR or the Vα24 chain found on invariant NK T cells (data not shown). Furthermore, their central memory phenotype as well as their absolute numbers are maintained throughout the course of SIV infection (Figure 5C and ref. 19). The ability of DN T cells from CD4-low mangabeys to produce Th1, Th2, and Th17 cytokines following stimulation as well as their ability to proliferate early, albeit transiently, in response to both SIV infection and influenza vaccination suggest these cells may be capable of performing multiple functions, including CD4 helper–like functions that may have enabled an influenza antibody response in the absence of CD4+ T cells. Similar to CD4+ T cells, which can be subdivided into Th1, Th2, and Th17 polarized cells, it is likely that not all DN T cells are able to respond to the same antigens and produce the same cytokines, and therefore assessing the different DN T cell subsets will be important. Additionally, some DN T cells may possess regulatory function, which could potentially contribute to controlling immune activation during nonpathogenic SIV infection. The potential of these cells to resist SIV infection due to the absence of CD4 is particularly important for their ability to maintain functionality. Indeed, an assessment of SIV DNA in purified DN T cells from a CD4-low SIV-infected mangabey determined that SIV levels were below the level of detection, providing further evidence that these cells are indeed SIV-resistant (similar to the CD4+CD8− T cells previously characterized in AGMs) (24). Taken together, these data suggest DN T cells play an important role in keeping SIV-infected mangabeys from progressing to simian AIDS by providing a memory T cell repertoire that is resistant to SIV infection and remains functional during SIV-induced CD4+ T cell loss. Prior to recent publications (9, 10, 19), it was thought that the maintenance of healthy levels of CD4+ T cells was critical for the nonpathogenic outcome observed in SIV-infected sooty mangabeys. More recently, it has been shown that sooty mangabeys have limited expression of CCR5 on CD4+ T cells, which could be important for protecting specific subsets of CD4+ T cells (such as Tcm) from virus-mediated depletion, thus leading to a better preservation of the overall CD4+ T cell pool (39, 40). However, in our cohort of SIV-infected mangabeys, the multitropic nature of the virus permits the infection of essentially all CD4+ T cells, thereby inducing a profound depletion of CD4+ T cells from all immunologic sites. Despite extensive CD4+ T cell depletion, our cohort is able to maintain immunologic health and has resisted clinical disease progression despite 3 or 9 years of AIDS-defining CD4+ T cell numbers. While there are likely multiple mechanisms contributing to the nonpathogenic outcome in SIV-infected sooty mangabeys, this study has revealed that DN T cells produce T helper cytokines, display a central-memory phenotype, and may compensate for the low levels of conventional CD4+ T cells in these mangabeys. The greater frequency of DN T cells in mucosal sites and their ability to upregulate IL-17, an important cytokine in maintaining mucosal integrity, is likely important for maintaining the low levels of immune activation observed in both CD4-healthy and CD4-low mangabeys. DN T cells have been identified in humans expressing a memory phenotype and possessing T cytotoxic, T helper, as well as regulatory T cell functions (39, 41, 42). It will be important to assess DN T cells in HIV-infected patients, particularly to determine whether these cells are preserving and functional in long-term nonprogressors. These efforts may lead to future immune therapies or vaccine modalities designed to modulate DN T cell function. Indeed, the main lesson we have learned to date from this cohort of SIV-infected CD4-low mangabeys may be that managing immune activation and bolstering the function of nontarget T cells through better vaccines and therapeutics has the potential to contribute to preserved immune function and a nonprogressive outcome in HIV infection even when CD4+ T cell levels become low.

**Methods**

**Animals and viral infection.** SM1 and SM2 were between 3 and 5 years of age when infected with SIV in the original study (19). They were inoculated intravenously with 1 ml of plasma transferred from mangabey FQ1, a naturally SIVsmm-infected mangabey at the Yerkes primate colony. The infection occurred in October 2000 and has previously been described (19). Before SIVsmm infection, virologic assessment determined that none of the mangabeys contained simian T cell lymphotropic virus or simian retrovirus. Fur-

### Table 1

Neutralizing antibody responses following influenza vaccination of SIV-infected CD4-low sooty mangabeys

<table>
<thead>
<tr>
<th>Days after 2nd vaccination</th>
<th>SM1</th>
<th>SM2</th>
<th>SM7</th>
<th>SM8</th>
<th>SM9</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WI*</td>
<td>SI*</td>
<td>WI</td>
<td>SI</td>
<td>WI</td>
</tr>
<tr>
<td>−7</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>0</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>7</td>
<td>160</td>
<td>80</td>
<td>5</td>
<td>40</td>
<td>640</td>
</tr>
<tr>
<td>14</td>
<td>320</td>
<td>226</td>
<td>5</td>
<td>80</td>
<td>2560</td>
</tr>
<tr>
<td>21</td>
<td>160</td>
<td>113</td>
<td>5</td>
<td>40</td>
<td>1280</td>
</tr>
<tr>
<td>28</td>
<td>80</td>
<td>80</td>
<td>5</td>
<td>40</td>
<td>640</td>
</tr>
</tbody>
</table>

*Antibody titers to the vaccine component H3N2 (WI). *Antibody titers to the vaccine component H1N1 (SI).
thermore, anti-sera analysis determined that all mangabeys except SM2 were seropositive for CMV/simian agent 6 and herpesvirus B. Passage of virus from SM2 to 3 additional SIV-negative mangabeys (SM7, SM8, and SM9) was performed by intravenous inoculation of 1.5 ml of plasma from the 303 wpi time point in October 2007. The viral inoculum contained SIV that was multitropic, able to use multiple coreceptors including CCR5 and CXCR4 (19). All protocols were approved by the institutional animal care and use committee at Emory University.

LN biopsies, rectal biopsies, and BAL. LN (axillary or inguinal) and rectal biopsies (RM) were performed as previously described (19).

Viral load analysis. SIVsmm plasma viral load was determined as previously described (16, 43).

Immunophenotyping of T cell subsets. Immunophenotypes of total PBMC and the assessment of cellular proliferation were performed by flow cytometric analysis with antibodies from BD Biosciences—Pharamingen. Phenotypic analysis was undertaken utilizing the following: allophycocyanin-Cy7–conjugated (APC-Cy7–conjugated) anti-CD3 (clone SP34), peridinin-chlorophyll proteins-Cy5.5–conjugated (PerCP-Cy5.5–conjugated) anti-CD8 (clone SK1), APC-conjugated anti-CD4 (clone SK3), FITC-conjugated anti-pan-CD (SA6.9), and FITC-conjugated anti-Vo24 (clone 6B11, gift from Lena Al-Harthi, Rush University Medical Center, Chicago, Illinois USA). Naïve and memory CD4+ T cells were defined utilizing PerCP-Cy5.5–conjugated anti-CD8 (clone SK1), FITC-conjugated anti-CD4 (clone SK3), PE-conjugated anti-CD28 (clone CD28.2), APC-conjugated anti-CD95 (clone DX2), and PE-Cy7–conjugated anti-CCR7 (clone 3D12). Cellular proliferation was assessed by intracellular staining with FITC-conjugated anti-Ki-67 (clone B56). All cells were stained with LIVE/DEAD fixable dead cell stain in violet (Invitrogen), fixed in 2% paraformaldehyde in PBS, and collected on an LSRII (BD Biosciences) or CyAn flow cytometer (DakoCytomation) and analyzed with FlowJo software (Treestar).

Assessment of SIV-specific T cell and antibody responses. SIV-specific peripheral blood CD8+ and DN T cell responses were assessed utilizing SIVsmm-specific peptides for Gag, Env, Pol, Nef, and Gag con (a consensus sequence generated from gag clones of SIVsmm subtype-1 and -2) and intracellular cytokine staining on PBMC samples obtained at 279 wpi (SM1 and SM2) or 52 wpi (SM7, SM8, SM9) as previously described (19, 44). SIV-specific antibody titers were determined as previously described (19). Briefly, detergent-disrupted SIV envelope proteins from SIVsmB7 captured on the Con A plate were exposed for 1 hour at room temperature to plasma Abs, mAbs, or plasma from SIV control mangabeys. To determine endpoint titers, the plates were washed with PBS and developed using peroxidase-conjugated goat anti-monkey IgG antibody and TM blue (Serologicals) as the substrate. Endpoint titers represent the last 2-fold dilution with an OD450 twice that of SIV-negative control animals.

Influenza vaccination and assessment of influenza-specific antibody responses. SMs 1, 2, 7, 8, and 9 received two 0.5 ml doses (15 μg of HA per dose) of a trivalent, inactivated influenza vaccine comprising H1N1-like virus,
H3N2-like virus, and B/Malaysia/2506/2004-like virus via intramuscular injection. Dose 1 was administered in November 2007, and dose 2 was given in September 2008. Influenza-specific antibodies were detected in plasma samples by microneutralization (MN) and HI assays as described previously (45). MN and HI titers greater than or equal to 4 times baseline titers were considered positive for seroconversion.

**Determination of coreceptor usage.** The coreceptor specificities of SIVsmm viruses were evaluated using methodology from the Trofile coreceptor tropism assay (Monogram Biosciences) as previously described (46, 47). Briefly, full-length envelope (env) genes were amplified from plasma samples by RT-PCR and were used to generate Env expression vector libraries. Env expression vector libraries were cotransfected into 293 cells together with an env-deleted luciferase-reporter HIV vector to generate SIVsmm Env pseudoviruses. Luciferase-reporter pseudoviruses were added to U87/CD4 cells expressing either CCR5 or CXCR4 in the absence and presence of coreceptor ligands as specificity controls. Infection of target cells was assayed by the addition of luciferase substrate and quantitation of luminescence, measured as RLUs. Specific infection of CCR5-positive cells only indicates that the viral population is R5 tropic. Specific infection via CXCR4 indicates positive for seroconversion.

**Isolation and characterization of DN T cells.** CD4+ T cells were isolated by magnetic bead isolation as follows utilizing beads from Miltenyi Biotec: T cells were depleted of CD4+ cells, CD8+ cells, and CD16+ cells, and the remaining CD3+ cells were collected by positive selection. The cells were rested overnight. and purity was assessed on an LSRII flow cytometer (BD Biosciences). Only greater than 97% pure CD T cells were used for stimulations. Briefly, 1 million DN T cells were stimulated for 4 hours with 0.5 μg/μl anti-CD3 (clone SP34) and 0.5 μg/μl anti-CD28 (clone CD28.2) antibodies (BD Biosciences). The stimulated cells were lysed in BLT buffer and RNA was extracted. After cDNA synthesis using random hexamers, the cDNAs of interest were cloned by real-time PCR using gene-specific primer-probe sets. The mRNA expression of cytokines was normalized to an internal control (GAPDH), and fold-changes were determined by the Ct method using Ct of specific cytokine genes in unstimulated and stimulated cells from the same animal.

**Statistics.** Statistical analyses were performed using GraphPad Prism 4.0 (GraphPad Software). A Mann-Whitney U test (nonparametric, 2-tailed, and unpaired) was performed to determine the differences between the values of absolute CD T cell counts of humans, rhesus macaques, and sooty mangabeys. Statistical significance was identified as P values less than 0.05 (95% CI).

**Acknowledgments**

We acknowledge the excellent animal care and veterinary staff at the Yerkes National Primate Center; F. Scott, A. Mobley, and S. Ehnert for technical assistance; M.P. Martin for helpful comments and discussions; L. Al-Harthi for discussions and supplying anti-Vo24 antibody; and A. Durudas, D. Kosub, M. Gasper, H. Jasan, L. Chen, and D. Fong for helpful comments. Work was supported by the NIH, including grants to the Yerkes Primate Center (PS1-RRO0165) as well as to D. Sodora (R56 AI087468 and R01 DE017541), and the Pendleton Trust.

Received for publication August 24, 2010, and accepted in revised form December 15, 2010.

**Address correspondence to:** Donald L. Sodora, Seattle Biomedical Research Institute, 307 Westlake Ave. N, Suite 500, Seattle, Washington, 98109, USA. Phone: 206.256.7143; Fax: 206.256.7229; E-mail: don.sodora@seattlebiomed.org.

research article